Department of Colorectal Cancer Surgery, Clinical Research Center of Colorectal Cancer, Tumor Hospital of Yun Nan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Surg Endosc. 2019 Mar;33(3):972-985. doi: 10.1007/s00464-018-6527-z. Epub 2018 Oct 29.
Transanal total mesorectal excision (TaTME) is positioned at the cutting edge of minimally invasive approach to mid- and low rectal cancer. This meta-analysis was to compare the short- and long-term outcomes of TaTME versus laparoscopic total mesorectal excision (LTME) and to evaluate the safety, efficacy, and possible superiority of TaTME.
A comprehensive search was conducted for randomized controlled trials (RCTs) and non-RCTs (NRCTs) comparing TaTME with LTME. Inter-group differences were evaluated via standardized mean differences and relative risks (RRs). All outcomes were analyzed using fixed effects or random effects models according to the heterogeneity. Statistical analysis was performed using Stata/SE 12.0 software.
Eleven studies (1 RCT and 10 NRCTs) with involving 757 patients were included. Among which, 361 patients underwent TaTME and 396 patients underwent LTME. Comparing the surgical and oncological quality of resection of TaTME with that of LTME, reports of TaTME indicated favorable outcomes considering mesorectal resection quality, circumferential resection margin involvement, intraoperative blood loss, conversions, and postoperative complications, while the differences between the two groups had no statistical significance in terms of distal resection margin, harvested lymph node, operation time, hospital stay, recurrence, 2-year overall survival (OS), and 2-year disease-free survival.
TaTME is a promising surgical technique and is fully a safe, efficacious, and diffusible alternative to LTME in managing mid- and distal rectal cancer. Larger scale, national, multicentric RCTs are warranted to further verify these results and the possible superiority of TaTME.
经肛门全直肠系膜切除术(TaTME)处于微创治疗中低位直肠癌的前沿。本荟萃分析旨在比较 TaTME 与腹腔镜全直肠系膜切除术(LTME)的短期和长期结果,并评估 TaTME 的安全性、疗效和可能的优势。
系统检索比较 TaTME 与 LTME 的随机对照试验(RCT)和非随机对照试验(NRCT)。采用标准化均数差和相对风险(RR)评估组间差异。所有结局均采用固定效应或随机效应模型根据异质性进行分析。统计分析采用 Stata/SE 12.0 软件。
纳入 11 项研究(1 项 RCT 和 10 项 NRCT),共 757 例患者。其中,361 例患者接受 TaTME,396 例患者接受 LTME。与 LTME 相比,TaTME 的手术和肿瘤学切除质量报告显示,TaTME 在直肠系膜切除质量、环周切缘受累、术中出血量、中转开腹和术后并发症方面具有优势,而两组在远端切缘、淋巴结清扫、手术时间、住院时间、复发、2 年总生存(OS)和 2 年无病生存方面无统计学差异。
TaTME 是一种有前途的手术技术,是治疗中低位直肠癌的一种安全、有效、可推广的 LTME 替代方法。需要更大规模、全国性、多中心 RCT 进一步验证这些结果和 TaTME 的可能优势。